XtalPi’s Ailux Strikes $345 Million Partnership with Eli Lilly to Co‑Develop Bispecific Antibodies
CompanyDeals

XtalPi’s Ailux Strikes $345 Million Partnership with Eli Lilly to Co‑Develop Bispecific Antibodies

Siemens Shanghai Gains NMPA Clearance for Prostate‑Cancer AI Detection Software
Medical Device

Siemens Shanghai Gains NMPA Clearance for Prostate‑Cancer AI Detection Software

Siemens Shanghai Gains NMPA Clearance for Prostate‑Cancer AI Detection Software
CompanyDeals

HBM’s Subsidiary Nona Biosciences Teams Up with Umoja Biopharma to Co‑Develop In‑Vivo CAR‑T Platforms

Shandong Jincheng Pharma Subsidiary Jincheng Taier to Sell Proxyl Vaginal Capsule Tech & MAH Rights to Shanghai Hemony for RMB 50 M
CompanyDeals

Shandong Jincheng Pharma Subsidiary Jincheng Taier to Sell Proxyl Vaginal Capsule Tech & MAH Rights to Shanghai Hemony for RMB 50 M

Sinotau Receives FDA NDA Approval for MK‑6240 Tau PET Imaging Agent
CompanyDrug

Sinotau Receives FDA NDA Approval for MK‑6240 Tau PET Imaging Agent

Baheal Pharma Locks CSL Behring Albumin Rights to Boost China’s Blood Product Supply
CompanyDeals

Baheal Pharma Locks CSL Behring Albumin Rights to Boost China’s Blood Product Supply

Prelude Therapeutics Revamps Pipeline: Incyte Option on JAK2V617F, KAT6A Degrader Takes Center Stage, SMARCA2 Paused
CompanyDeals

Prelude Therapeutics Revamps Pipeline: Incyte Option on JAK2V617F, KAT6A Degrader Takes Center Stage, SMARCA2 Paused

UCB Wins FDA Approval for KYGEVVI in Rare Mitochondrial Disease TK2d
CompanyDrug

UCB Wins FDA Approval for KYGEVVI in Rare Mitochondrial Disease TK2d

Dizal Highlights Breakthrough Findings for golidocitinib and birelentinib at ASH 2025
CompanyDrug

Dizal Highlights Breakthrough Findings for golidocitinib and birelentinib at ASH 2025

Jiangsu Vcare’s VC004 Joins NMPA’s SPARK Oncology Program
CompanyDrug

Jiangsu Vcare’s VC004 Joins NMPA’s SPARK Oncology Program

Pfizer’s Q3 2025 Results: COVID‑19 Sales Slide While Eliquis Soars
Company

Pfizer’s Q3 2025 Results: COVID‑19 Sales Slide While Eliquis Soars

Jiangsu Hengrui Secures Priority Review for HRS‑5965 in China’s Rare‑Disease Portfolio
CompanyDrug

Jiangsu Hengrui Secures Priority Review for HRS‑5965 in China’s Rare‑Disease Portfolio